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Aims Nitroxyl provokes vasodilatation and inotropic and lusitropic effects in animals via post-translational modification of
thiols. We aimed to compare effects of the nitroxyl donor cimlanod (BMS-986231) with those of nitroglycerin (NTG)
or placebo on cardiac function in patients with chronic heart failure with reduced ejection fraction (HFrEF).
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Methods
and results
In a randomized, multicentre, double-blind, crossover trial, 45 patients with stable HFrEF were given a 5 h intravenous
infusion of cimlanod, NTG, or placebo on separate days. Echocardiograms were done at the start and end of each
infusion period and read in a core laboratory. The primary endpoint was stroke volume index derived from the left
ventricular outflow tract at the end of each infusion period. Stroke volume index with placebo was 30± 7 mL/m2 and
was lower with cimlanod (29± 9 mL/m2; P = 0.03) and NTG (28± 8 mL/m2; P = 0.02). Transmitral E-wave Doppler
velocity on cimlanod or NTG was lower than on placebo and, consequently, E/e′ (P = 0.006) and E/A ratio (P = 0.003)
were also lower. NTG had similar effects to cimlanod on these measurements. Blood pressure reduction was similar
with cimlanod and NTG and greater than with placebo.
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Conclusion In patients with chronic HFrEF, the haemodynamic effects of cimlanod and NTG are similar. The effects of cimlanod
may be explained by venodilatation and preload reduction without additional inotropic or lusitropic effects. Ongoing
trials of cimlanod will further define its potential role in the treatment of heart failure.
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Graphical Abstract
The nitroxyl donor cimlanod (BMS-986231) has similar haemodynamic effects to nitroglycerin (NTG), including venodilatation with consequent
cardiac preload reduction and systemic blood pressure reduction in patients with heart failure with reduced ejection fraction. EDV, end-diastolic
volume; EF, ejection fraction; ESV, end-systolic volume; GLS, global longitudinal strain; LA, left atrial; LV, left ventricular; LVOT, left ventricular outflow
tract; PBO, placebo; RA, right atrial; SV, stroke volume; SVI, stroke volume index; TR, tricuspid regurgitation.
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Introduction
Although vasodilators, primarily nitrates, are often used to
treat patients with acute heart failure provided they are not
hypotensive,1,2 there is no compelling evidence that they improve
clinical outcomes.1 Conventional inotropic agents are reserved
principally for use in patients with low blood pressure (BP)
and, despite potential short-term haemodynamic benefits, have
been associated with harm.1–3 These harmful effects have been
attributed mainly to elevated concentrations of intracellular cal-
cium and increases in heart rate, myocardial oxygen consumption,
and both atrial and ventricular arrhythmias.1,4
Nitroxyl (HNO) is chemically related to nitric oxide but
pre-clinical models and early phase studies suggest that its
mechanisms of action are markedly different.5,6 HNO causes
post-translational modification of thiol residues and, in particular,
cardiomyocyte sarcoplasmic reticulum Ca2+ adenosine triphos-
phatase, ryanodine receptors, phospholamban, and myofilament
proteins.6–9 Importantly, in vitro studies demonstrated inotropic
and lusitropic effects by increasing calcium sensitivity and calcium
handling efficiency rather than by increasing intracellular calcium
































. positive inotropic and lusitropic that effects that were independent
of beta-adrenergic signalling.11 In addition to these potentially
attractive myocardial effects, HNO also causes vasodilatation via
soluble guanylate cyclase.12 These properties suggest that HNO
might be effective for the treatment of patients hospitalized for
heart failure.13
The haemodynamic effects of cimlanod (BMS-986231), an HNO
donor, have been investigated in patients with advanced heart
failure, congestion, and a reduced left ventricular ejection frac-
tion (LVEF).13,14 In that Phase II dose escalation study, intra-
venous (IV) infusion of cimlanod for 6 h was well tolerated,
reduced systemic arterial and intra-cardiac filling pressures, and
increased cardiac index (CI), as measured by thermodilution
but not by the Fick method.14 Any potential effect on CI may
have been secondary to vasodilator effects rather than inotropy
per se.
We conducted the StandUP-Imaging trial (NCT03357731) to
evaluate the effects of a continuous 5 h IV infusion of cimlanod
on cardiac performance measured by echocardiography in patients
with chronic stable heart failure with reduced ejection frac-
tion (HFrEF). Nitroglycerin (NTG), a vasodilator without direct
inotropic effects, was used as an active comparator.
© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Methods
This was a multicentre, prospective, Phase II, randomized, double-blind,
placebo- and active-controlled trial with a crossover design.13 Contin-
uous 5 h infusions of cimlanod were compared with infusions of NTG
and with placebo in patients with chronic stable HFrEF. The study was
approved by the relevant health authorities and by the Institutional
Review Board of each participating site. All study participants provided
written informed consent.
Patients
We enrolled patients aged ≥18 years with a clinical diagnosis of heart
failure (New York Heart Association class I to III), an echocardiographic
LVEF of ≤40% and plasma N-terminal prohormone of B-type natri-
uretic peptide (NT-proBNP) ≥125 pg/mL [or B-type natriuretic pep-
tide (BNP) ≥35 pg/mL]. Patients were required to be in sinus rhythm,
on stable therapy for heart failure [including an angiotensin-converting
enzyme inhibitor (ACEi), angiotensin receptor blocker (ARB), or
angiotensin receptor–neprilysin inhibitor (ARNI) and mineralocorti-
coid receptor antagonist plus beta-blockers, as tolerated], and have
good quality echocardiographic images. The main exclusion criteria at
screening or pre-randomization were systolic BP (SBP) <110 mmHg
or heart rate <50 or >90 bpm. Patients with heart rate <50 bpm were
excluded to avoid the confounding influence of bradycardia upon dias-
tolic function and we excluded patients with heart rate >90 bpm to
permit optimal Doppler analysis. Patients with paced rhythm were
excluded, as were those with restrictive, obstructive, or hypertrophic
cardiomyopathy, severe valvular disease, or prior aortic or mitral valve
repair or replacement. Patients who had been hospitalized for heart
failure in the previous month or had an acute coronary or cerebrovas-
cular event in the previous 3 months were ineligible.
Procedures
Participants were asked to omit their usual heart failure medications
on each study day. In a crossover design, participants were exposed
to each of the three interventions (cimlanod, NTG, and placebo) in
random order. Randomization was via centralized electronic interactive
response technology. Each treatment period included a 5 h IV infusion,
followed by a washout period of 5 to 28 days. In order to maintain
blinding, the infusions were administered according to a pre-specified
flow rate and had similar appearance and packaging. The target doses
were 12 μg/kg/min for cimlanod and 80 μg/min for NTG, which were
attained after a short initial up-titration period (10 min at 25% of target
dose followed by 10 min at 50% of target dose followed by target
dose thereafter, providing BP tolerability criteria were met). BP and
heart rate were recorded prior to the infusion, every 30 min for the
first hour, and then hourly until the end of the infusion. They were
recorded again at 1, 2, and 3.5 h after the end of the infusion. In the
event of a decrease in SBP during infusions, an algorithm was used
to down-titrate, interrupt, or discontinue the infusion. If a patient
experienced SBP of 80 to 90 mmHg without symptoms of hypotension,
the infusion rate was reduced by 50%. If SBP fell below 80 mmHg
(and remained <80 mmHg following a repeated measurement within
15 min), or if the patient experienced symptoms of hypotension
(regardless of BP), the infusion was interrupted for at least 1 h. It was
subsequently resumed at 50% of the prior dose, provided that SBP had
recovered to ≥105 mmHg and symptoms of hypotension had resolved.



















































































.. been interrupted for low BP, resumed, and an episode of hypotension
(or symptoms of hypotension) re-occurred. After the 5 h infusion,
patients remained in the study facility for a further 3.5 h but were
discharged on the same day unless there had been prolonged or
symptomatic hypotension or other events of concern, in which case
patients were kept overnight.
A core laboratory performed all echocardiographic analyses blinded
to infusion assignment (Brigham and Women’s Hospital, Boston, MA,
USA). Reproducibility data are provided in online supplementary Meth-
ods S1. An echocardiogram was done at screening and was submitted
for review and confirmation of eligibility on the basis of LVEF and imag-
ing quality. At least two echocardiograms were done on the first day
of each period (prior to infusion and near the end of the infusion
between hour 4 and hour 5). In the event of premature interruption
of an infusion, an echocardiogram was done as soon as possible. A
pre-specified echocardiographic protocol for image acquisition was
created by the core laboratory. Recordings were optimized for endo-
cardial border definition and echocardiographic contrast agent used
when required. Sonographers at each site were trained by the core
laboratory and underwent a certification process. The core laboratory
worked with individual sites to identify the proper equipment settings
to optimize images.
The primary outcome of interest was stroke volume index (SVI)
derived from the left ventricular (LV) outflow tract velocity time
integral (VTI) as measured by Doppler at the end of infusion of
cimlanod compared with placebo. Secondary outcomes of interest
included the effect of cimlanod compared with that of NTG or placebo
on SVI and on other LV systolic and diastolic indices (LVEF, tissue
Doppler, LV diastolic function, including mitral inflow velocities and
other indices such as LV power index and global longitudinal strain). LV
volumes, elastance, and myocardial performance (Tei) index were also
measured, as were left atrial (LA) size and function and right ventricular
size and function.
Safety was monitored by physical examination, standard clinical bio-
chemistry and haematology tests, and urinalysis. Twelve-lead electro-
cardiograms were recorded before and after each infusion period. The
occurrence of any adverse events (AEs) was recorded from the start of
the infusion until 24 h after the end of the infusion. Patients were con-
tacted by telephone on the day after each infusion to enquire about
potential AEs. Serious AEs were recorded from the date of informed
consent and up to 30 days after the end of the last infusion.
Sample size calculation and statistical
analyses
Sample sizes were calculated based on comparison of post-baseline
SVI values, adjusting for the differences in the baseline value. Sample
size calculations assumed an increase of SVI of 4.5 mL/m2 from
baseline, relative to placebo, an inter-individual standard deviation of
10 mL/m2, and intra-individual correlations for the difference between
assessments of 0.7. A sample size of approximately 36 participants, with
data from the treatment periods being compared, was estimated to
provide 90% power, with a type I error probability of 0.05 (two-sided).
The sample size was increased by 20% to compensate for the possibility
of missing data due to patient withdrawal.
Comparisons between placebo and cimlanod were done using a
mixed model repeated measures analysis that examined within-subject
differences, controlling for treatment sequence, treatment period, and
specific treatment (i.e. cimlanod, NTG, or placebo), with the difference
in the treatment period baselines as co-variates. All randomized
© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 1 Patient disposition. BNP, B-type natriuretic peptide; NT-proBNP, N-terminal pro B-type natriuretic peptide; NTG, nitroglycerin;
PBO, placebo. *≥ 1 reason for screen failure possible.
patients who started study drug infusion in at least one assessment
period were included in the final analysis. No adjustments were made
for multiple comparisons. Statistical significance was defined by a
P-value of <0.05. All data analyses were performed using SAS version
9.3 or higher (SAS Institute, Inc., Cary, NC, USA).
Results
Enrolment of participants
Between December 2017 and March 2019, patients were random-
ized at nine sites in the United Kingdom, Netherlands, United
States of America, and Japan. Overall, 45 participants were ran-
domized and received at least one infusion and were included in the
final analysis on an intention-to-treat basis (Figure 1). Thirty-nine
participants completed all three infusions.
Baseline characteristics
Of the 45 participants, 37 (82%) were men and the mean age
was 64± 12 years. Most (89%) were white and 71% had ischaemic
heart disease (Table 1). Median (interquartile range) NT-proBNP
and BNP levels were 505 (325–1111) pg/mL and 177 (136–325)
pg/mL, respectively (Table 1). The main baseline medications are
outlined in Table 1.
Echocardiographic measurements
Mean baseline SVI derived from the LV outflow tract VTI was low
at the beginning of all infusion periods. At the end of the infusion
of cimlanod, SVI was significantly lower than it was at the end of
placebo infusion (SVI with cimlanod: 29± 9 mL/m2 vs. SVI with
placebo: 30± 7 mL/m2; P = 0.027). SVI was also lower at the end
of NTG infusion than it was at the end of placebo (SVI with NTG:
28± 7 mL/m2; P = 0.017 vs. SVI with placebo) (Table 2). The effects
of cimlanod and NTG on SVI were similar (P = 0.8) (Table 2 and
Figure 2).
At the end of NTG infusion, LV end-diastolic and end-systolic
























































.. higher, although the effect was modest. Similar trends were seen
with cimlanod, although only LV end-systolic volume was signifi-
cantly different from placebo. The effects of NTG and cimlanod,
including upon mean LV global longitudinal strain, cardiac power
index, LV Tei index, LV end-systolic elastance (Ees) and arterial
elastance (Ea) were similar (Table 2).
Peak early transmitral velocity (E wave) was similarly reduced
by cimlanod and NTG compared with placebo (P = 0.008 and
P = 0.014 for cimlanod and NTG vs. placebo, respectively). There
were no significant differences in peak active transmitral velocity
(A wave) or lateral early diastolic myocardial velocity (e′). There-
fore, although E/A and E/e′ ratios were lower at the end of both
cimlanod and NTG infusions compared with placebo, these dif-
ferences were driven primarily by changes in E wave velocity and
not by other markers of diastolic performance. When compared
with placebo, LA volume was reduced by cimlanod (P = 0.002 vs.
placebo) and NTG (P < 0.001 vs. placebo). The effects of cimlanod
and NTG upon LA volume were similar (P = 0.73 for cimlanod vs.
NTG) (Table 2).
Echocardiographic contrast agent was used in four patients.
Blood pressure and heart rate effects
Overall mean SBP decreased during all infusions: it dropped by
5 ±13 mmHg during placebo, by 19± 15 mmHg during cimlanod
(P < 0.0001 vs. placebo), and by 15± 18 mmHg during NTG
(P = 0.0024 vs. placebo) (Figure 3A). Recovery of SBP after the
end of the infusion was similar for cimlanod and NTG. The
pattern of change for diastolic BP was similar for cimlanod and
NTG (Figure 3B). Although there was a small reduction in mean
heart rate during all infusion periods, this was not statistically
significant compared with baseline or across groups. Mean heart
rate reduction was 1 ± 11 bpm during placebo, 2 ± 8 bpm during
cimlanod, and 1 ± 8 bpm during NTG (Figure 3C).
Safety
During placebo infusion, no patient met the pre-specified BP crite-
ria for dose reduction, interruption, or cessation. During cimlanod,
© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 1 Patient baseline characteristics
Patient characteristic
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Patients, n 45
Age, years 64±12
Male sex 37 (82)
Race
White














BMI, kg/m2 27± 5
Heart rate, bpm 66±11
SBP, mmHg 129±15
DBP, mmHg 74±11




















Data are presented as mean± standard deviation, n (%), or median [interquartile
range]. Due to rounding, percentage values may not total 100%.
BMI, body mass index; BNP, B-type natriuretic peptide; DBP, diastolic blood pres-
sure; eGFR, estimated glomerular filtration rate; LVEF, left ventricular ejection
fraction; NT-proBNP, N-terminal pro B-type natriuretic peptide; SBP, systolic
blood pressure.
the infusion was discontinued because of hypotension in two par-
ticipants, while another four (10%) required protocol-mandated
dose reduction as a result of low BP but went on to complete the
total 5 h infusion period at 50% of target dose. One patient who
experienced hypotension was on chronic treatment with sacubi-
tril/valsartan (although, per protocol, this had been omitted on the
morning of the study). One patient discontinued NTG because of
chest pain and hypotension and, similar to cimlanod, four patients
(9%) required a BP-related dose reduction but went on to complete
the 5 h infusion period at 50% of target dose.
There was no incidence of arrhythmia during placebo or cim-
lanod infusion. During NTG, one patient had very brief (eight
beats) non-sustained ventricular tachycardia, and another had brief,
self-terminating supraventricular tachycardia.
Most AEs were mild or moderate in severity and were reported
in eight participants (20%) receiving placebo, 15 participants (36%)
receiving cimlanod and 15 participants (34%) receiving NTG.
The most common AE reported with cimlanod was headache



















































































.. was reported by seven participants (16%) during NTG and by
two patients (5%) during placebo. There were two serious AEs.
One participant reported abdominal discomfort during placebo
infusion and had acutely deranged liver function tests. Further
investigation confirmed acute cholecystitis. Another participant
had marked hypotension and bradycardia (vasovagal pre-syncope)
during infusion of NTG. He was admitted to hospital overnight for
observation and made an uncomplicated recovery.
Discussion
We have demonstrated that cimlanod, a novel HNO donor, has
haemodynamic effects similar to those of NTG in ambulatory
patients with chronic stable HFrEF. We did not demonstrate
an inotropic effect of cimlanod. Although cimlanod improved
echocardiographic markers of diastolic function, this appeared to
reflect venodilatation and preload reduction rather than a direct
lusitropic effect.
Almost all patients in the trial were on an ACEi/ARB/ARNI
and a beta-blocker, although only a minority were treated with
a mineralocorticoid receptor antagonist. Patients had well con-
trolled symptoms and many did not require diuretic therapy.
Natriuretic peptides were only modestly elevated, and patients
were excluded if they had had a recent decompensation of heart
failure. Furthermore, patients with an SBP <110 mmHg were
excluded. Consequently, the participants in the trial reflect patients
with ambulatory heart failure without substantial volume over-
load. This is in contrast to the patients included in an earlier
study examining dose-ranging effects of IV cimlanod in patients
with advanced heart failure and elevated pulmonary capillary
wedge pressure (≥20 mmHg).14 In those patients, cimlanod evoked
dose-dependent reductions in cardiac filling pressures and an
increase in CI assessed by thermodilution, but not when assessed
by the Fick method. Heart rate was unaffected by cimlanod in that
study and therefore any increase in CI must have been due to
an increase in stroke volume, caused by a reduction in afterload,
improved myocardial contractility, or both.14
In the current study, cimlanod led to a small but significant
reduction in SVI when compared with placebo. This effect on SVI,
the primary outcome measure, was similar to that of NTG and
contrasts with the earlier study described above. The reduction
in SVI in our study most likely reflects a reduction in preload
(as a result of venous dilatation) in patients who already had
relatively low filling pressures. This effect might be different in
patients with more severe heart failure and high LV end-diastolic
pressures.15 In such patients, CI might increase when afterload
is reduced despite a reduction in intra-cardiac filling pressure.15
Indeed, in an historical invasive haemodynamic study of patients
after myocardial infarction, IV NTG was associated with a rise
in cardiac output in patients with high LV filling pressures, while
in those with normal LV filling pressures NTG caused cardiac
output to fall.16 Cimlanod and NTG reduced LV volumes, which
can be attributed to altered loading conditions and accounts for
the small increase in LVEF with NTG. Importantly, the effects of
cimlanod on sensitive measures of systolic function including LV
© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 2 Echocardiographic measurements before and at the end of 5 h of infusion of placebo, nitroglycerin, or
cimlanod
Placebo NTG Cimlanod
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SVI, mL/m2 29 ± 7 30 ± 7 29 ± 7 28 ± 7 0.017 30 ± 9 29 ± 9 0.027 0.846
SV, mL 57 ±16 58 ±14 57 ±14 55 ±15 0.036 59 ±17 57 ±17 0.045 0.837
LVEDV, mL 160 ± 52 160 ± 54 163 ± 51 155 ± 50 0.009 165 ± 54 155 ± 45 0.065 0.914
LVESV, mL 111 ± 43 110 ± 42 112 ± 41 105 ± 41 0.006 114 ± 45 106 ± 39 0.046 0.918
LVEF, % 32 ± 7 32 ± 7 32 ± 7 34 ± 7 0.039 32 ± 8 33 ± 8 0.177 0.839
Mean LV GLS, % −11.6 ± 3.1 −12.0 ± 2.9 −11.5 ± 3.2 −11.4 ± 3.1 0.006 −11.3 ± 3.3 −11.9 ± 3.5 0.705 0.105
Cardiac power index, W/m2 0.40 ± 0.11 0.41 ± 0.14 0.38 ± 0.08 0.35 ± 0.09 0.063 0.44 ± 0.17 0.34 ± 0.10 0.007 0.103
LV Tei index 0.6 ± 0.2 0.7 ± 0.2 0.6 ± 0.3 0.7 ± 0.2 0.009 0.7 ± 0.3 0.8 ± 0.4 0.012 0.6
LV Ees, mmHg/mL 3.5 ±1.4 3.2 ±1.0 3.3 ±1.3 2.8 ±1.0 0.033 3.3 ±1.3 2.6 ±1.1 0.174 0.342
Ea, mmHg/mL 2.2 ± 0.7 2.0 ± 0.5 2.2 ± 0.7 1.9 ± 0.5 0.364 2.1 ± 0.7 1.9 ± 0.6 0.685 0.711
Ea/Ees 0.69 ± 0.23 0.69 ± 0.4 0.76 ± 0.36 0.76 ± 0.30 0.044 0.76 ± 0.45 0.90 ± 0.43 0.075 0.981
Peak E wave velocity, cm/s 63 ± 24 59 ±17 67 ± 25 54 ± 23 0.014 66 ± 23 53 ±19 0.008 0.753
Peak A wave velocity, cm/s 72 ± 21 77 ± 24 75 ± 21 76 ±19 0.687 74 ± 22 75 ± 20 0.876 0.798
E/A ratio 0.9 ± 0.5 0.8 ± 0.3 0.9 ± 0.5 0.7 ± 0.3 0.005 1.0 ± 0.5 0.7 ± 0.3 0.003 0.904
Lateral e′ , cm/s 7.3 ± 2.5 7.2 ± 2.5 7.3 ± 2.5 7.2 ± 2.1 0.231 7.5 ± 2.6 8.1 ± 2.3 0.994 0.073
E/e′ ratio 9.2 ± 4.2 9.4 ± 4.1 10.0 ± 4.5 7.8 ± 2.7 0.016 9.8 ± 4.2 7.0 ± 2.5 0.006 0.503
LA volume, mL 57.7 ±15.0 58.8 ±17.0 61.8 ±16.8 54.3 ±18.0 <0.001 62.0 ±17.0 55.3 ±18.7 0.002 0.73
RA volume, mL 15.5 ± 3.6 15.6 ± 4.1 15.4 ± 3.7 14.8 ± 2.9 0.639 14.8 ± 2.6 14.8 ± 2.9 0.759 0.009
Peak TR velocity, cm/s 240 ± 67 261 ± 31 251 ± 74 232 ± 49 0.098 248 ± 60 235 ± 32 NA 0.556
TAPSE, cm 1.7 ± 0.3 1.8 ± 0.4 1.6 ± 0.3 1.6 ± 0.3 0.092 1.7 ± 0.4 1.6 ± 0.4 0.042 0.879
RV EDA, cm2 20.8 ± 6.0 20.4 ± 5.4 20.2 ± 5.9 20.1 ± 7.2 0.693 19.4 ± 5.1 19.7 ± 4.4 0.983 0.426
RV ESA, cm2 11.7 ±11.4 11.4 ± 3.3 11.1 ± 4.5 11.3 ± 4.4 0.146 11.4 ± 3.4 11.2 ± 3.2 0.894 0.399
RV FAC, % 44.0 ± 7.0 43.9 ± 6.8 45.3 ± 8.3 44.7 ± 7.0 0.919 41.3 ± 5.9 43.3 ± 6.9 0.466 0.751
Data are presented as mean± standard deviation. Statistically significant P-values are indicated in bold.
e′ , lateral early diastolic myocardial velocity; Ea, arterial elastance; EDA, end-diastolic area; Ees, end-systolic elastance; ESA, end-systolic area; FAC, fractional area change; GLS, global longitudinal strain;
LA, left atrium; LV, left ventricular; LVEDV, left ventricular end-diastolic volume; LVEF, left ventricular ejection fraction; LVESV, left ventricular end-systolic volume; NA, not assessed (because of a low
number of measures); NTG, nitroglycerin; RA, right atrium; RV, right ventricle; SV, stroke volume; SVI, stroke volume index derived from the left ventricular outflow tract area; TAPSE, tricuspid annular
plane systolic excursion; TR, tricuspid regurgitation.
global longitudinal strain, cardiac power index and LV Tei index
were similar to those of NTG and did not suggest an inotropic
effect. LV Ees and Ea were also similar at the end of NTG and
cimlanod, as was Ea/Ees, a marker of ventriculo–arterial coupling
efficiency.17 Two of the most striking effects of cimlanod were
reductions in LA volume and E wave velocity. These changes were
also evoked by NTG and are consistent with preload reduction.18
The effects on E wave velocity account for the observed reduc-
tions in E/e′ and E/A ratios. Neither e′ velocity nor A wave
velocity was altered by either cimlanod or NTG and, as such,
these apparently beneficial effects on diastolic indices reflect
reductions in cardiac preload and filling pressures rather than direct
lusitropy.
The effects of cimlanod on heart rate and BP were not the
primary focus of the current study. Defining the BP effects of
cimlanod in patients with heart failure-related hospitalization is the
aim of the StandUP-AHF trial.13 However, in the current study,
cimlanod had broadly similar effects on BP and heart rate as
NTG, although the onset of the BP-lowering effect appeared to
be slightly delayed compared with NTG. It is notable that, despite
the fall in BP and SVI during cimlanod and NTG, there was no
appreciable reflex tachycardia. The reduction in SVI associated with
cimlanod and NTG was small and we believe that the hypotensive
effect of these agents primarily reflects arterial vasodilatation





































. cannot be fully excluded. Although patients did not take their
usual medications on the morning of the study infusion, a residual
effect of beta-blockers may account for the absence of a rise in
heart rate.
Infusion visits were separated by at least 5 days and, given the
short half-lives of NTG and cimlanod, no carry-over effect of these
agents upon haemodynamics would be expected. We minimized
the potential for changes in baseline haemodynamics over time by
including patients with stable heart failure symptoms who had had
no change in heart failure medications (nor of their dosage) within
the 2 weeks prior to enrolment.
The addition of NTG as an active control arm is a major
strength of the study. The dose of NTG was chosen to produce
an equivalent reduction in pulmonary capillary wedge pressure to
the 12 μg/kg/min dose of cimlanod. Given the remarkable similarity
of the observed haemodynamic effects of NTG and cimlanod,
it seems that we chose an appropriate active comparator dose.
Furthermore, we have provided comprehensive data pertaining
to the haemodynamic effects of NTG which, although in routine
clinical use, has no compelling evidence demonstrating that it
improves clinical outcomes. Continuous IV infusion of cimlanod
for 5 h was well tolerated and had a safety profile similar to
that of NTG when administered to subjects with chronic heart
failure and impaired systolic function. No new safety concerns
were identified. However, it is notable that almost one quarter of
© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 2 Stroke volume index (SVI) derived from the left ven-
tricular outflow tract area. (A) Absolute SVI (pre-infusion vs.
post-infusion). (B) Change in SVI vs. baseline in the presence
of placebo (PBO), nitroglycerin (NTG), or cimlanod. Data are
presented as mean± standard error of the mean. *P < 0.05 vs.
placebo at end of infusion.
patients receiving cimlanod experienced headache, albeit of mild
severity.
Limitations
We assume that the preload reduction induced by cimlanod is
mediated by venodilatation. However, cimlanod might reduce con-
gestion by increasing diuresis or diuretic sensitivity, which would
differentiate it from NTG. While there is currently no evidence
to support or refute this hypothesis and it was not addressed in
the current study, this is the focus of the ongoing StandUP-Kidney
study.13 Secondly, while we administered infusions over 5 h to
achieve steady-state drug bioavailability, this period is shorter than
that often used for NTG in clinical practice. NTG-mediated vaso-
motor effects are associated with tachyphylaxis19 and, although
there are data to suggest that this may not be an issue with HNO
donors,20,21 infusions in the current study were not of sufficient
duration to address this question. The StandUP-AHF trial ran-
domized patients to 48 h IV infusion of cimlanod or placebo13
and should provide some insight to this question, albeit without
direct comparison to NTG. Invasive assessment using conductance
catheters to create pressure–volume loops may provide greater




















































































Figure 3 Mean (± 95% confidence interval) change in blood
pressure (BP) and heart rate during and after study infusions. (A)
Mean systolic BP at baseline, during, and after study infusions.
(B) Mean (± 95% confidence interval) diastolic BP at baseline,
during, and after study infusions. (C) Mean (± 95% confidence
interval) change in heart rate during and after study infusions.
NTG, nitroglycerin; PBO, placebo.
we wished to avoid an invasive approach, and ensured an appro-
priate sample size was recruited to allow robust comparisons to
be made with echocardiographic assessment of SVI as the primary
outcome of interest.
Conclusion
In patients with chronic stable HFrEF, infusion of cimlanod, a novel
HNO donor, causes venous and arterial vasodilatation but does
not appear to exert inotropic or direct lusitropic effects. The
haemodynamic profile is similar to that of NTG.
© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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